GVK Biosciences

Medivir restructures, partners with GVK BIO

Wednesday, June 17, 2015


Medivir,
a research based pharmaceutical company based in Sweden, has announced a reorganization within its Discovery Research department, increasing its focus within the core areas of oncology and infectious diseases, and a partnership with GVK Biosciences Private (GVK BIO) of Hyderabad in India, designed to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility.

[Read More]

EMA recommends suspending medicines over flawed studies

Monday, January 26, 2015

A number of medicines for which authorization in the European Union (E.U.) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, according to the EMA. The recommendation is based on findings from an inspection that raised concerns about how GVK conducted studies at the Hyderabad site on behalf of marketing authorization holders.

[Read More]

GVK Bio launches new clinical development service offering

Monday, July 21, 2014

India-based GVK Biosciences has unveiled a new brand, Clinogent, in the clinical development industry. Clinogent provides end-to-end clinical development services, from bioequivalence studies for generic pharma to late phase patient-based clinical studies. It offers solutions to complex data analysis and medical communication problems.

[Read More]

GVB BIO licenses biomarker database to FDA

Thursday, February 7, 2013

GVK Biosciences, a discovery, research and development organization providing a broad spectrum of services, is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the FDA. The GOBIOM database, which has the latest and recently updated information on all the biomarkers reported in various clinical and preclinical studies, will be beneficial to the FDA in its Biomarker Qualification Process.

[Read More]